The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRKR | -60.53% | -91.18% | -38.46% | -100% |
| S&P | +15.66% | +86.6% | +13.29% | +667% |
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.23M | -36.0% |
| Market Cap | $11.55M | -54.1% |
| Market Cap / Employee | $2.31M | 0.0% |
| Employees | 5 | -37.5% |
| Net Income | -$1,998.66K | 13.4% |
| EBITDA | -$2,136.73K | 11.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.94M | 110.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -87.60% | -24.2% |
| Return On Invested Capital | -81.54% | -1.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,735.88K | -328.5% |
| Operating Free Cash Flow | -$2,735.88K | -328.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.72 | 0.71 | 1.18 | 0.96 | -62.78% |
| Price to Sales | 4.29 | 2.40 | 3.96 | 3.19 | -31.68% |
| Price to Tangible Book Value | 3.72 | 0.71 | 1.18 | 0.96 | -62.78% |
| Enterprise Value to EBITDA | -2.36 | 0.01 | -2.24 | 1.87 | -127.69% |
| Return on Equity | -65.8% | -97.3% | -144.7% | -110.7% | 38.75% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
